Abstract
Neurodegenerative diseases carry a huge burden in terms of human suffering and economic cost. In spite of advances in the field of neurology, there is still no effective cure. A combination of novel genomic approaches and techniques such as chromatin immunoprecipitation sequencing (ChIP-seq) and RNA-seq that enable high-quality data could provide better understanding of transcriptional and epigenetic signatures useful for both biomarker development and drug discovery in neurodegenerative diseases. This chapter provides detailed protocols of the different steps required to generate a successful ChIP-seq and RNA-seq library. ChIP-seq protocol starts with cell collection and fixation, chromatin preparation, immunoprecipitation, and finally library preparation. RNA-seq protocol described in this chapter starts with the isolation of peripheral blood mononuclear cells (PBMCs), RNA isolation from cells, and library preparation. The ChIP-seq protocol is optimized for human neuroglioma cells (H4), and RNA-seq protocol is optimized for PBMCs, but both protocols can be adapted to different cell types with minor modifications. The obtained libraries are suitable for sequencing on Illumina GAIIx platform.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Anderson AN, Roncaroli F, Hodges A, et al. Chromosomal profiles of gene expression in Huntington's disease. Brain. 2008;131(Pt 2):381–8.
Cao X, Yeo G, Muotri AR, et al. Noncoding RNAs in the mammalian central nervous system. Annu Rev Neurosci. 2006;29:77–103.
Chaturvedi RK, Hennessey T, Johri A, et al. Transducer of regulated CREB-binding proteins (TORCs) transcription and function is impaired in Huntington's disease. Hum Mol Genet. 2012;21:3474–88.
Cui L, Jeong H, Borovecki F, et al. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell. 2006;127:59–69.
Desjardins S, Belkai E, Crete D, et al. Effects of chronic morphine and morphine withdrawal on gene expression in rat peripheral blood mononuclear cells. Neuropharmacology. 2008;55:1347–54.
Euskirchen GM, Rozowsky JS, Wie CL, et al. Mapping of transcription factor binding regions in mammalian cells by ChIP: comparison of array‐ and sequencing‐based technologies. Genome Res. 2007;6:898–909.
Issidorides MR, Stefanis CN, Varsou E, et al. Altered chromatin ultrastructure in neutrophils of schizophrenics. Nature. 1975;258:612–4.
Khoo SK, Petillo D, Kang UJ, et al. Plasma-based circulating microRNA biomarkers for Parkinson’s disease. J Parkinsons Dis. 2012;2(4):321–31.
Li X, Khanna A, Li N, et al. Circulatory miR34a as an RNAbased, noninvasive biomarker for brain aging. Aging. 2011;3:985–1002.
Martins M, Rosa A, Guedes LC, et al. Convergence of miRNA expression profiling, α-synuclein interacton and GWAS in Parkinson’s disease. PLoS One. 2011. doi:10.1371/journal.pone.0025443.
Provencal N, Suderman MJ, Guillemin C, et al. The signature of maternal rearing in the methylome in rhesus macaque prefrontal cortex and T cells. J Neurosci. 2012;32:15626–42.
Satoh J, Kawana N, Yamamoto Y. Pathway analysis of ChIP-Seq-based NRF1 target genes suggests a logical hypothesis of their involvement in the pathogenesis of neurodegenerative diseases. Gene Regul Syst Bio. 2013;7:139–52.
Siddiqui A, Chinta SJ, Mallajosyula JK, et al. Selective binding of nuclear alpha-synuclein to the PGC1alpha promoter under conditions of oxidative stress may contribute to losses in mitochondrial function: implications for Parkinson’s disease. Free Radic Biol Med. 2012;53:993–1003.
Sullivan PF, Fan C, Perou CM. Evaluating the comparability of gene expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet. 2006;141B:261–8.
Ursini G, Bollati V, Fazio L, et al. Stress-related methylation of the catechol-O-methyltransferase Val 158 allele predicts human prefrontal cognition and activity. J Neurosci. 2011;31:6692–8.
Weinmann AS, Farnham PJ. Identification of unknown target genes of human transcription factors using chromatin immunoprecipitation. Methods. 2002;26:37–47.
Wells J, Farnham PJ. Characterizing transcription factor binding sites using formaldehyde crosslinking and immunoprecipitation. Methods. 2002;26:48–56.
Yacoubian TA, Cantuti-Castelvetri I, Bouzou B, et al. Transcriptional dysregulation in a transgenic model of Parkinson disease. Neurobiol Dis. 2008;29:515–28.
Yuferov V, Nielsen DA, Levran O, et al. Tissue-specific DNA methylation of the human prodynorphin gene in post-mortem brain tissues and PBMCs. Pharmacogenet Genomics. 2011;21:185–96.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this protocol
Cite this protocol
Gotovac, K., Borovečki, F., Habek, M. (2015). Location Analysis and Expression Profiling Using Next-Generation Sequencing for Research in Neurodegenerative Diseases. In: Jain, K. (eds) Applied Neurogenomics. Neuromethods, vol 97. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-2247-5_3
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2247-5_3
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-2246-8
Online ISBN: 978-1-4939-2247-5
eBook Packages: Springer Protocols